• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Innoviva Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8/6/25 4:21:37 PM ET
    $INVA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $INVA alert in real time by email
    false 0001080014 0001080014 2025-08-06 2025-08-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, DC 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): August 6, 2025

     

    INNOVIVA, INC.

    (Exact Name of Registrant as Specified in its Charter)

     

    Delaware 000-30319 94-3265960
    (State or Other Jurisdiction of
    Incorporation)
    (Commission File Number) (I.R.S. Employer Identification
    Number)

     

    1350 Old Bayshore Highway,
    Suite 400

    Burlingame, California 94010

    (650) 238-9600

    (Addresses, including zip code, and telephone numbers, including area code, of principal executive offices)

     

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, par value $0.01 per share   INVA   The NASDAQ Global Select Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

     

     

     

     

     

    Item 2.02. Results of Operations and Financial Condition

     

    On August 6, 2025, Innoviva, Inc. (the “Company”) issued a press release regarding its results of operations and financial condition for the quarter ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report.

     

    The information in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

     

    Item 9.01. Financial Statements and Exhibits

     

    (d) Exhibits

     

    99.1   Press Release dated August 6, 2025
    104   Cover Page Interactive File (the cover page tags are embedded within the Inline XBRL document)

     

    - 2 - 

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      INNOVIVA, INC.
       
    Date: August 6, 2025 By: /s/ Pavel Raifeld
        Pavel Raifeld
        Chief Executive Officer

     

    - 3 - 

    Get the next $INVA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $INVA

    DatePrice TargetRatingAnalyst
    8/11/2025$45.00Outperform
    Oppenheimer
    7/14/2025$40.00Buy
    H.C. Wainwright
    7/11/2025$26.00Overweight
    Cantor Fitzgerald
    3/7/2025$55.00Sector Outperform
    Scotiabank
    6/18/2024Overweight
    Cantor Fitzgerald
    7/20/2022$16.00Neutral
    Goldman
    2/23/2022$10.00 → $12.00Underweight
    Morgan Stanley
    2/11/2022$28.00Buy
    EF Hutton
    More analyst ratings

    $INVA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Innoviva Specialty Therapeutics' Antimicrobial Therapies ZEVTERA® and XACDURO® Nominated for the 2025 Prix Galien USA Best Pharmaceutical Product Award

    Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (NASDAQ:INVA), announced today that two of the company's infectious disease therapies, ZEVTERA® (ceftobiprole medocaril sodium for injection) and XACDURO® (sulbactam/durlobactam for injection) have been nominated for the prestigious 2025 Prix Galien USA Award, "Best Pharmaceutical Product." "We are honored that both ZEVTERA and XACDURO have been recognized among the most innovative therapies of the year by The Galien Foundation," said Pavel Raifeld, Chief Executive Officer of Innoviva, Inc. "These nominations reflect the strength of our scientific innovation and the urgent clinical need our therapies address." The Prix Gali

    8/13/25 8:00:00 AM ET
    $INVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Innoviva Reports Second Quarter 2025 Financial Results; Highlights Recent Company Progress

    Strong royalties portfolio performance with $67.3 million in revenue IST achieved U.S. net product sales of $29.0 million, reflecting 54% year-over-year growth ZEVTERA (ceftobiprole medocaril sodium, for injection) launched in the U.S. Zoliflodacin NDA accepted by FDA with Priority Review; PDUFA date set for December 15, 2025 Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today reported financial results for the second quarter ended June 30,

    8/6/25 4:05:00 PM ET
    $INVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 2025

    FDA is expected to notify Innoviva Specialty Therapeutics regarding its decision to conduct an Advisory Committee Meeting in the Day 74 letter If approved, zoliflodacin would be the first new antibiotic for treating gonorrhea in decades Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (NASDAQ:INVA), in collaboration with the Global Antibiotic Research & Development Partnership (GARDP), today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review for the New Drug Application (NDA) for zoliflodacin, an investigational first-in-class, single dose, spiropyrimidinetrione oral antibiotic for the treatment of uncomplicated gonorrhea in adult

    6/12/25 7:00:00 AM ET
    $INVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INVA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Accounting Officer Zhen Marianne covered exercise/tax liability with 992 shares, decreasing direct ownership by 2% to 50,320 units (SEC Form 4)

    4 - Innoviva, Inc. (0001080014) (Issuer)

    5/22/25 4:15:51 PM ET
    $INVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Basso Stephen was granted 1,353 shares and covered exercise/tax liability with 237 shares, increasing direct ownership by 5% to 23,518 units (SEC Form 4)

    4 - Innoviva, Inc. (0001080014) (Issuer)

    5/22/25 4:15:16 PM ET
    $INVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Small Derek A was granted 12,077 shares, increasing direct ownership by 52% to 35,249 units (SEC Form 4)

    4 - Innoviva, Inc. (0001080014) (Issuer)

    5/21/25 9:36:44 PM ET
    $INVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INVA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Oppenheimer initiated coverage on Innoviva with a new price target

    Oppenheimer initiated coverage of Innoviva with a rating of Outperform and set a new price target of $45.00

    8/11/25 10:03:31 AM ET
    $INVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Innoviva with a new price target

    H.C. Wainwright initiated coverage of Innoviva with a rating of Buy and set a new price target of $40.00

    7/14/25 8:52:08 AM ET
    $INVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on Innoviva with a new price target

    Cantor Fitzgerald initiated coverage of Innoviva with a rating of Overweight and set a new price target of $26.00

    7/11/25 8:12:59 AM ET
    $INVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INVA
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Innoviva Inc.

    SCHEDULE 13G/A - Innoviva, Inc. (0001080014) (Subject)

    8/13/25 4:11:12 PM ET
    $INVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Innoviva Inc.

    SCHEDULE 13D/A - Innoviva, Inc. (0001080014) (Filed by)

    8/12/25 9:38:41 PM ET
    $INVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Innoviva Inc.

    10-Q - Innoviva, Inc. (0001080014) (Filer)

    8/6/25 4:27:03 PM ET
    $INVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INVA
    Leadership Updates

    Live Leadership Updates

    View All

    Innoviva Appoints Stephen Basso as Chief Financial Officer

    Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" and "the Company"), a diversified holding company with a portfolio of royalties and other healthcare assets, today announced the appointment of Stephen Basso as its Chief Financial Officer, effective August 21, 2023. "We are excited to welcome Stephen to our executive leadership team and believe the Company will benefit greatly from his background and experience," said Pavel Raifeld, Chief Executive Officer of Innoviva. "I look forward to working with Stephen to advance our strategy and create shareholder value." Mr. Basso brings more than 30 years of experience in the financial services industry and financial leadership in the pharmaceutical ind

    8/25/23 4:52:00 PM ET
    $INVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Armata Pharmaceuticals Announces New Financing and Leadership Transition to Accelerate Novel Bacteriophage Therapeutics

    Signs new $25 million credit agreement and extension of existing secured convertible credit agreement Appoints world‐renowned healthcare leader Dr. Deborah L. Birx as Chief Executive Officer MARINA DEL REY, Calif., July 11, 2023 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen‐specific bacteriophage therapeutics for antibiotic‐resistant and difficult‐to‐treat bacterial infections, today announced that it has entered into a credit and security agreement with Innoviva Strategic Opportunities LLC, a wholly‐owned subsidiary of Innoviva, Inc. (NASDAQ:INVA) (collectively, "Innoviva"). The gross proceeds of t

    7/11/23 8:00:00 AM ET
    $ARMP
    $INVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Innoviva Announces Retirement of Board Chairman

    Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" and "the Company") and George Bickerstaff, III, Chairman of the Board of Directors of the Company (the "Board") today announced that Mr. Bickerstaff would not stand for reelection at the Company's 2023 Annual Meeting. Following the Meeting, assuming that all other members of the Board are reelected, the Board will be comprised of six members. Mr. Bickerstaff indicated that he is stepping down from the Board to focus on other professional and philanthropic pursuits, which includes his role as chair of the Board of Trustees for the International Vaccine Institute. "Serving Innoviva as Board Chairman has been an honor," said Mr. Bickerstaff. "I am v

    4/28/23 5:30:00 PM ET
    $INVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INVA
    Financials

    Live finance-specific insights

    View All

    Innoviva Reports Second Quarter 2025 Financial Results; Highlights Recent Company Progress

    Strong royalties portfolio performance with $67.3 million in revenue IST achieved U.S. net product sales of $29.0 million, reflecting 54% year-over-year growth ZEVTERA (ceftobiprole medocaril sodium, for injection) launched in the U.S. Zoliflodacin NDA accepted by FDA with Priority Review; PDUFA date set for December 15, 2025 Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today reported financial results for the second quarter ended June 30,

    8/6/25 4:05:00 PM ET
    $INVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Innoviva Reports First Quarter 2025 Financial Results; Highlights Recent Company Progress

    Core royalty platform maintained strong performance, generating $61.3 million in revenue Innoviva Specialty Therapeutics achieved U.S. net product sales of $26.4 million for the first quarter, reflecting 52% year-over-year growth Continued momentum across therapeutics platform with regulatory submissions for zoliflodacin and commercial launch of ZEVTERA® (ceftobiprole) progressing as planned Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today rep

    5/7/25 4:05:00 PM ET
    $INVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Innoviva Reports Fourth Quarter and Full Year 2024 Financial Results; Highlights Recent Company Progress

    Core royalty platform continues to deliver with GSK royalties of $66.0 million for the fourth quarter and $255.6 million for the full year Innoviva Specialty Therapeutics achieved U.S. net product sales of $24.9 million for the fourth quarter and $80.9 million for the full year, reflecting 47% year-over-year growth Therapeutics platform strengthened with acquisition of exclusive U.S. commercialization and distribution rights to ZEVTERA® (ceftobiprole), launching mid-2025 Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeuti

    2/26/25 4:04:00 PM ET
    $INVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INVA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Innoviva Inc.

    SC 13D/A - Innoviva, Inc. (0001080014) (Filed by)

    11/14/24 4:17:40 PM ET
    $INVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Innoviva Inc.

    SC 13G - Innoviva, Inc. (0001080014) (Subject)

    5/13/24 1:58:00 PM ET
    $INVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by Innoviva Inc.

    SC 13D - Innoviva, Inc. (0001080014) (Subject)

    5/8/24 3:38:11 PM ET
    $INVA
    Biotechnology: Pharmaceutical Preparations
    Health Care